SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of Gemcitabine and Cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Authors
Geldart, TChester, J
Casbard, A
Crabb, S
Elliott, Tony
Protheroe, A
Huddart, R
Mead, G
Barber, J
Jones, R
Smith, J
Cowles, R
Evans, J
Griffiths, G
Affiliation
Royal Bournemouth Hospital, Bournemouth, UKIssue Date
2014-11-20
Metadata
Show full item recordAbstract
Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve participants were recruited and received up to six 21-d cycles of cisplatin 70mg/m(2) (intravenously [IV], day 1) and gemcitabine 1000mg/m(2) (IV, days 1 and 8) combined with sunitinib 37.5mg (orally, days 2-15). Following review of toxicity after the first six patients, the sunitinib dose was reduced to 25mg for all patients. Overall response rate was 64%, with response noted in 37 of 58 patients. At 6 mo, 30 of 58 assessable patients (52%; 90% confidence interval [CI], 40-63%) were progression free. Median overall survival was 12 mo (95% CI, 9-15) and was heavily influenced by Bajorin prognostic group. Grade 3-4 toxicities were predominantly haematologic and limited the deliverability of the triple SGC regimen. The trial did not meet its prespecified primary end point of >60% patients progression free at 6 mo. Cumulative myelosuppression led to treatment delays of gemcitabine and cisplatin and dose reduction and/or withdrawal of sunitinib in the majority of cases. The triple-drug combination was not well tolerated. Phase 3 evaluation of the triple SGC regimen in advanced transitional cell carcinoma is not recommended.Citation
SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of Gemcitabine and Cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma. 2014: Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2014.11.003PubMed ID
25465968Type
ArticleISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2014.11.003